TREVENA INCTRVN

時価総額

$1万

PER

中枢神経系疾患向け医薬品開発の新興企業。主力の静注オピオイドOLINVYKを展開。2020年8月FDA承認、2021年Q1に商業化開始。2024年4月に販売支援縮小と戦略的選択肢の検討を表明。米国中心展開。

	2014年 12月31日	2015年 12月31日	2016年 12月31日	2017年 12月31日	2018年 12月31日	2019年 12月31日	2020年 12月31日	2021年 12月31日	2022年 12月31日	2023年 12月31日
Net loss	-	-	-	-	-	-	-	-	-54	-40
Depreciation	239,390	207,897	0	0	1	1	1	0	0	0
Stock-based compensation	2	3	6	6	4	3	3	4	4	3
Paid-in-Kind Interest	33,442	179,747	1	1	1	0	0	-	0	2
Inventory Write-down	-	-	-	-	-	-	-	-	2	1
Value of warrants issued for exercise inducement	-	-	-	-	-	-	-	-	-	5
Fair Value Adjustment of Warrants	-122,412	70,387	-0	-0	-0	0	0	-0	-11	-2
Fair value of warrants in excess of proceeds	-	-	-	-	-	-	-	-	7	-
Returns reserve adjustment	-	-	-	-	-	-	-	-	0	0
Accretion of bond discount on marketable securities	-	-	-	-	0	0	-	-	0	-
Change in right-of-use asset	-	-	-	-	-	-0	-0	-0	-0	-1
Accounts receivable, prepaid expenses and other assets	-3,196,559	1	-0	-1	-1	1	-1	2	-1	-1
Inventories	-	-	-	-	-	-	-	2	1	-0
Operating lease liabilities	-	-	-	-	-	-0	-1	-1	-1	-1
Accounts payable, accrued expenses and other liabilities	4	3	7	-8	-1	-1	3	2	-1	-1
Net cash used in operating activities	-	-	-	-	-25	-24	-21	-50	-51	-33
Purchases of property and equipment	440,381	361,247	1	3	0	-	0	0	0	0
Maturities of marketable securities	-	-	116	99	69	79	4	-	33	-
Purchases of marketable securities	71	57	77	63	48	54	-	-	33	-
Net cash used in investing activities	-	-	-	-	21	26	3	-0	0	-0
Proceeds from Issuance of Common Stock	107	90	32	21	33	10	101	8	-	8
Payment of employee withholding taxes on vested restricted stock units	-	-	-	-	-	0	1	0	0	0
Proceeds from Issuance of Common Stock, Warrants and Prefunded Warrants	-	-	-	-	-	-	-	-	8	1
Proceeds from Warrant Exercises	-	-	-	-	-	-	-	-	-	2
Finance lease payments	-	-	-	-	-	0	0	0	0	0
Proceeds From Prefunded Warrants Exercised	-	-	-	-	-	-	-	-	-	0
Proceeds From Issuance Of Long Term Debt And Proceeds From Issuance Of Warrants	-	-	-	-	-	-	-	-	2	-
Proceeds from loan payable	-	16	-	10	-	-	-	-	14	15
Net cash provided by financing activities	-	-	-	-	21	-2	95	8	24	26
Net decrease in cash, cash equivalents and restricted cash	-	-	-	-7	16	-1	77	-42	-28	-7
Interest Paid, Net	-	-	-	-	1	1	0	-	1	1
Reclassification of Warrant Liability Upon Exercise of Prefunded Warrants	-	-	-	-	-	-	-	-	-	2